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Obesity and associated metabolic disorders have been implicated in liver carcinogenesis;
however, there are little data on the role of obesity-related biomarkers on liver cancer risk.
We studied prospectively the association of inflammatory and metabolic biomarkers with
risks of hepatocellular carcinoma (HCC), intrahepatic bile duct (IBD), and gallbladder and
biliary tract cancers outside of the liver (GBTC) in a nested case-control study within the
European Prospective Investigation into Cancer and Nutrition. Over an average of 7.7 years,
296 participants developed HCC (n5 125), GBTC (n5 137), or IBD (n5 34). Using risk-
set sampling, controls were selected in a 2:1 ratio and matched for recruitment center, age,
sex, fasting status, and time of blood collection. Baseline serum concentrations of C-reactive
protein (CRP), interleukin-6 (IL-6), C-peptide, total high-molecular-weight (HMW) adipo-
nectin, leptin, fetuin-a, and glutamatdehydrogenase (GLDH) were measured, and incidence
rate ratios (IRRs) and 95% confidence intervals (CIs) were estimated using conditional
logistic regression. After adjustment for lifestyle factors, diabetes, hepatitis infection, and adi-
posity measures, higher concentrations of CRP, IL-6, C-peptide, and non-HMW adiponectin
were associated with higher risk of HCC (IRR per doubling of concentrations5 1.22; 95%
CI5 1.02-1.46; P 5 0.03; 1.90; 95% CI5 1.30-2.77; P 5 0.001; 2.25; 95% CI5 1.43-
3.54; P 5 0.0005; and 2.09; 95% CI5 1.19-3.67; P 5 0.01, respectively). CRP was associ-
ated also with risk of GBTC (IRR5 1.22; 95% CI5 1.05-1.42; P 5 0.01). GLDH was
associated with risks of HCC (IRR5 1.62; 95% CI5 1.25-2.11; P 5 0.0003) and IBD
(IRR5 10.5; 95% CI5 2.20-50.90; P 5 0.003). The continuous net reclassification index
was 0.63 for CRP, IL-6, C-peptide, and non-HMW adiponectin and 0.46 for GLDH, indi-
cating good predictive ability of these biomarkers. Conclusion: Elevated levels of biomarkers
of inflammation and hyperinsulinemia are associated with a higher risk of HCC, independ-
ent of obesity and established liver cancer risk factors. (HEPATOLOGY 2014;60:858-871)
Abbreviations: AFP, alpha-fetoprotein; anti-HCV, antibodies to hepatitis C virus; DAUC, area under the receiver operating characteristics curve; BMI, body
mass index; CI, confidence interval; CRP, C-reactive protein; EPIC, European Prospective Investigation into Cancer and Nutrition; GBTC, gallbladder and biliary
tract cancers outside of the liver; GLDH, glutamatdehydrogenase; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus infection; HCC, hepatocellular carci-
noma; HCV, hepatitis C virus infection; HMW, high molecular weight; IBD, intrahepatic bile duct cancer; ICD-10, the 10th Revision of the International Classi-
fication of Diseases; ICD-O-2, the 2nd edition of the International Classification of Diseases for Oncology; IDI, relative integrated discrimination improvement;
IL-6, interleukin-6; IR, insulin resistance; IRR, incidence rate ratio; NRI, continuous net reclassification improvement; ROC, receiver operating characteristics
curve; sOB-R, soluble leptin receptor; WHtR, waist-to-height ratio.
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L
iver cancer is the sixth most commonly diag-
nosed cancer worldwide, with an estimated
749,700 new cases in 2008; it is also known as
one of the most lethal tumors, with 5-year survival
rates below 5%.1 Incidence rates show substantial geo-
graphic variation, with higher rates in Southeast Asia
and sub-Saharan Africa and lower rates in North
America and Western Europe.1,2 Although in recent
years incidence rates have declined in many high-risk
areas, they have also increased in low-risk regions.1,2
The increasing trends of obesity and related metabolic
consequences, such as diabetes mellitus, were suggested
to have contributed to the higher disease rates in West-
ern societies.3,4 In this vein, recent estimates, based on
data from the European Prospective Investigation into
Cancer and Nutrition (EPIC), have suggested obesity to
account for 16% of hepatocellular carcinoma (HCC),
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the predominant type of liver cancer.5 Obesity is charac-
terized by chronic subclinical inflammation and hyper-
insulinemia, which may promote hepatocyte injury
and steatohepatitis.6,7 Thus, the adipose tissue-derived
proinflammatory cytokine, interleukin-6 (IL-6),8 which
induces secretion of C-reactive protein (CRP) in the
liver, may contribute to hepatocarcinogenesis.9,10 Insulin
may stimulate cell proliferation and inhibit apoptosis.11
Fetuin-a, a plasma protein exclusively secreted by the
liver in humans, is up-regulated in liver dysfunction,12
correlates with key enzymes in glucose and lipid metab-
olism,13 and thereby is possibly implicated in hepatic
insulin resistance (IR) and fat accumulation.13 Finally,
the adipose tissue-derived hormones, leptin and adiponectin,
which are involved in regulating insulin sensitivity and
inflammation, may directly or indirectly promote fibrosis,
cirrhosis, and, potentially, HCC.14-17 Despite experimental
evidence, only a few prospective epidemiological studies
examined the association between inflammatory or meta-
bolic biomarkers and risk of liver cancer in a general (mostly
healthy) population.18-20 However, such information is
important because evidence on the relation between obesity-
related biomarkers and risk of liver cancer may provide clues
for understanding the underlying etiological mechanisms. In
addition, identification of biomarkers, which quantify meta-
bolically active adipose tissue beyond anthropometric
parameters, may be a complementary approach for defining
an “obesity phenotype” relevant for liver cancer. Ultimately,
in the general population, these candidate biomarkers may
be potentially utilized to refine cancer risk assessment and
improve strategies for cancer prevention.21
Therefore, we studied prospectively the association
of biomarkers of inflammation (CRP and IL-6), hyper-
insulinemia (C-peptide), liver fat accumulation (fetuin-
A), liver damage (glutamate dehydrogenase; GLDH),
and circulating adipokine concentrations (adiponectin
and leptin) with risk of HCC, intrahepatic bile duct
cancer (IBD) and gallbladder and biliary tract cancers
outside of the liver (GBTC) in a nested case-control
study within the EPIC cohort.
Patients and Methods
Study Population. The EPIC study was designed
to identify nutritional, lifestyle, metabolic, and genetic
risk factors for cancer.22 In brief, between 1992 and
2000 approximately 520,000 apparently healthy men
and women from 10 European countries (Denmark,
France, Germany, Greece, Italy, the Netherlands, Nor-
way, Spain, Sweden, and the UK), 35-75 years of age,
were enrolled. For the present study, the latest dates of
complete follow-up for cancer incidence and vital sta-
tus in the EPIC centers ranged from 2002 to 2006.
Incident cases were defined using both the 10th
Revision of the International Classification of Diseases
(ICD-10)23and the 2nd edition of the International Clas-
sification of Diseases for Oncology (ICD-O-2).24 Respec-
tive histologies, methods used for diagnosis of cancer, as
well as alpha-fetoprotein (AFP) levels were reviewed to
exclude metastatic cases or other types of liver cancers.
After exclusion of cases with other types of cancer preced-
ing the index case (n5 18), metastatic cases (n523), or
cases with ineligible histology (n5 31), 125 HCC
(including 105 histologically verified cases), 35 IBD, and
137 GBTC incident cases (including 51 cases of gallblad-
der cancer) were identified, occurring over an average of
7.7 years (Supporting Fig. 1). HCC was defined as tumor
in the liver (ICD-10 C22.0 with morphology codes
ICD-O-2 “8170/3”and “8180/3”; n5 125). IBD cancer
was defined as tumor in the intrahepatic bile ducts (ICD-
10 C22.1; all morphology codes except ICD-O-2 “8162/
3”; n5 35). GBTC cancers were defined as tumors of
the gallbladder (ICD-O-2 C23.9; n5 51], ampulla of
Vater (ICD-10 C24.1; n5 28), extrahepatic bile duct
cancer (ICD-10 C24.0; n5 33), cancer of overlapping
lesion of the biliary tract (ICD-10 C.24.8; n5 1], cancer
of the biliary tract, unspecified (C24.9; n5 21), and
Klatskin tumors (ICD-10 C22.1 with morphology code
ICD-O-2 “8162/3”; n5 3).
Nested Case-Control Study. Using risk-set sam-
pling, 2 controls per case were selected at random
from all cohort members who had donated a blood
sample, were alive and free of cancer at the time of
liver cancer diagnosis of the index case, and were
matched to the case on study center, sex, age (612
months), date of blood collection (62 months), fast-
ing status (<3, 3-6, or >6 hours), and time of the day
(63 hours) at blood collection. Women were addition-
ally matched according to menopausal status (pre-,
peri-[unknown], or postmenopausal) and exogenous
hormone use (yes, no, or missing) at blood donation.
After 1 IBD case and 2 respective controls were
excluded because of missing information on any of the
biomarkers, the current analysis was based on 125
HCC, 34 IBD, and 137 GBTC incident cases.
Laboratory Assays. As described in detail else-
where,25 blood samples were collected at baseline, proc-
essed, divided into heat-sealed straws, and stored in
liquid nitrogen freezers (2196C). Approval was
obtained from the ethics review board of the Interna-
tional Agency for Research on Cancer (Lyon, France)
and the local review boards pertaining to the participat-
ing institutions. Researchers were blinded to the
case-control status of the samples. Measurement of bio-
markers was performed at the Institute of Clinical
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Chemistry, University of Magdeburg, Magdeburg, Ger-
many. CRP was measured using a high-sensitivity assay
on a Turbidimetrie Modular system (Roche, Mannheim,
Germany) with reagent and calibrators from Roche. IL-
6 was measured using the ECLIA Modular system
(Roche). C-peptide was measured with the Immulite
2000 (Siemens AG, Erlangen, Germany). Adiponectin,
leptin, and fetuin-A concentrations were measured using
enzyme-linked immunosorbent assay (ALPCO Diagnos-
tics, Salem, NH, USA, for adiponectin; Biovendor, Hei-
delberg, Germany, for leptin and fetuin-a, respectively)
with a minimum detectable limit of 0.04, 0.17, and 5.0
ng/mL, respectively. To quantify high-molecular-weight
(HMW) adiponectin, serum samples were pretreated
with a protease that specifically digests low-molecular-
weight and medium-molecular-weight adiponectin.
Non-HMW adiponectin was calculated by subtracting
HMW adiponectin from total adiponectin. GLDH was
measured on a DGKC optimized, 37C, Modular-
System (Roche). Hepatitis B surface antigen (HBsAg)
and antibodies to hepatitis C virus (anti-HCV)were
measured at the Centre de Biologie Republique (Lyon,
France) using ARCHITECT chemiluminescent micro-
particle immunoassays (Abbott Diagnostics, Rungis,
France), as previously described.5 For biomarker meas-
urements below the detection limit, we assigned half of
the lower limit of detection (Supporting Table 1).
Statistical Analyses. Case-control differences were
assessed using the Student paired t test, Wilcoxon’s
signed-rank test, McNemar’s test, or Bowker’s test of
symmetry, where appropriate.26 Spearman’s partial cor-
relation coefficients, adjusted for age at recruitment
and sex, were estimated to assess correlations among
biomarkers in controls.
Conditional logistic regression was used to investigate
the associations between biomarkers and risk of HCC,
IBD, and GBTC cancers. Incidence rate ratios (IRRs),
estimated from odds ratios as derived from the risk-set
sampling design27 and 95% confidence intervals (CIs),
were computed. Associations were assessed on the con-
tinuous scale by calculating the relative risks associated
with an increase of log-transformed biomarker concen-
trations by log2, which corresponds to a doubling of the
concentrations on the original scale. In addition, associ-
ations were assessed on a categorical scale according to
tertiles based on the biomarker distributions among
controls. P values for trends were calculated using
median biomarker levels within tertiles among controls.
Multivariable conditional logistic regression models
were constructed, including a priori–chosen covariates,
primarily based on existing evidence on liver cancer risk
factors.5 To account for potential liver injury at baseline,
all multivariable models were additionally adjusted for
GLDH, a marker of liver damage.28 Multivariable models
were also mutually adjusted for the different biomarkers.
Restricted cubic spline regression was used to assess nonli-
nearity using Wald’s test.29 Models were fitted with 5th,
50th, and 95th percentile of the biomarker distribution
and median biomarker concentration among the controls
were used as a reference.
Fig. 1. Association of metabolic biomarkers (continuously per doubling of concentrations) and risk of HCC in the multivariable modela before
and after adjustment for GLDH as a marker of liver damage. aMultivariable model taking into account matching factors: study center; gender;
age (612 months); date (62 months); fasting status (<3, 3-6, or >6 hours); and time of the day (63 hours) at blood collection. Women
were additionally matched according to menopausal status (pre-, peri- [unknown], or postmenopausal) and exogenous hormone use (yes, no, or
missing) at blood donation. Further adjusted for education (no school degree or primary school, secondary school, high school, or missing),
smoking (never, former, current, or missing), alcohol at baseline, drinking status at baseline (nondrinker or drinker), diabetes (no, yes, or miss-
ing), coffee (g/day), HBsAg/anti-HCV (negative, positive, or missing), BMI, and WHtR adjusted for BMI. Note: Analyses were based on overall
293 cases and 581 controls for adiponectin, fetuin-a, and leptin, 293 cases and 577 controls for CRP and GLDH, 277 cases and 549 controls
for C-peptide, and 214 cases and 419 controls for IL-6.
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To assess the predictive capacity of the biomarkers
beyond established liver cancer risk factors, we estimated
the change in the area under the receiver operating char-
acteristics (ROC) curve (DAUC), the relative integrated
discrimination improvement (IDI), and the continuous
net reclassification improvement (NRI).30,31 We used
SAS’s “ROCCONTRAST” statement based on the non-
parametric approach of DeLong et al.32 and a
“%reclassification_phreg” macro by M€uhlenbruch and
Bernigau extended for Cox’s regression.33 The DAUC is
produced by taking the difference in discrimination met-
rics between the models with and without the new pre-
dictor variable. Similarly, IDI is defined as a difference
in discrimination slopes in these models. The relative
IDI is calculated as the ratio of IDI over the discrimina-
tion slope of the model without the new predictor. The
continuous NRI (NRI[>0]) is obtained by the relative
increase in the predicted probabilities for subjects who
experienced events, compared to the decrease for subjects
who did not. We considered NRI(>0) values above 0.6
to indicate strong, those around 0.4 intermediate, and
those below 0.2 weak reclassification improvement.34
We repeated the analyses after excluding individuals
with self-reported diabetes at baseline and those with pos-
itive HBsAg/anti-HCV test, high alcohol consumers, and
cases that occurred during the first 2 years of follow-up.
To reduce potential misclassification of cases, we also
explored associations after restricting the analyses on
HCC to histologically confirmed cases. We also restricted
the analysis of GBTC to gallbladder cancer only. Finally,
we repeated all analyses after excluding biomarker meas-
urements, which have fallen below the detection limit
(Supporting Table 1). Two-sided P values below 0.05
were considered to indicate statistical significance. All sta-
tistical analyses were performed using the Statistical Anal-
ysis System (SAS) (version 9.2), Enterprise Guide User
Interface (version 4.3); SAS Institute, Inc., Cary, NC.
Results
Baseline Characteristics and Demographic
Data. As compared to the controls, cases of HCC
were more likely to be smokers, have high alcohol and
low coffee intake, be less educated, diabetics, and
HBsAg/anti-HCV infection positive (Table 1). HCC
cases had significantly higher body mass index (BMI),
waist circumference, and waist-to-height ratio (WHtR),
as well as higher concentrations of CRP, IL-6, C-peptide,
adiponectin, leptin, and fetuin-A, compared to controls.
GBTC cases had higher WHtR and CRP concentra-
tions, compared to controls. IBD cases had higher BMI,
waist circumference, and WHtR, as well as higher leptin
and C-peptide concentrations, compared to their con-
trols (Table 1). There was a moderate correlation among
the biomarkers (Table 2). GLDH was weakly positively
correlated with BMI, leptin, CRP, and C-peptide and
inversely with adiponectin (Table 2).
Logistic Regression Analysis. In the final multivari-
able model—conditioned on matching factors and after
adjustment for education, smoking, alcohol, coffee
intake, diabetes, hepatitis B virus/hepatitis C virus
(HBV/HCV) infection, BMI, and WHtR—higher pre-
diagnostic concentrations of CRP, IL-6, C-peptide, and
non-HMW adiponectin were associated with higher risk
of HCC (IRR continuously per doubling of concen-
trations5 1.22; 95% CI5 1.02-1.46; P5 0.03; 1.90;
95% CI5 1.30-2.77; P5 0.001; 2.25; 95% CI5 1.43-
3.54; P5 0.0005; and 2.09; 95% CI5 1.19-3.67;
P5 0.01, respectively; Table 3). Higher levels of GLDH
were also significantly associated with a higher risk of
HCC (IRR5 1.62; 95% CI5 1.25-2.11; P5 0.0003;
Table 3). There was no evidence for a nonlinear shape
of these associations (Supporting Fig. 2). HMW adipo-
nectin, leptin, and fetuin-A were not significantly associ-
ated with HCC risk in the multivariable-adjusted
model. When additionally adjusted for GLDH, the asso-
ciations remained unaltered, except for CRP, which was
no longer statistically significant (Fig. 1). Mutual adjust-
ment of biomarkers also did not substantially affect the
results, with the exception of non-HMW adiponectin,
which was no longer significant after IL-6 was added to
the multivariable model (IRR continuously per doubling
of concentrations5 1.07; 95% CI: 0.30-3.82; P5 0.24).
Higher CRP concentrations were associated with
higher risk of GBTC (multivariable-adjusted IRR5 1.22;
95% CI5 1.05-1.42; P5 0.01; Table 4). This associa-
tion remained statistically significant when the analyses
were restricted to gallbladder cancer only (IRR5 1.55;
95% CI5 1.15-2.08; P5 0.003; Supporting Table 3).
Higher levels of GLDH were associated with a higher
risk of IBD (IRR5 10.5; 95% CI5 2.2-50.9;
P5 0.003; Table 5), but not with GBTC (IRR5 1.15;
95% CI5 0.95-1.40; P5 0.15; Table 4). The remaining
biomarkers were not statistically significantly related to
either GBTC or IBD cancers (Tables 4 and 5).
Predictive Capacity of Biomarkers. Addition of
CRP, IL-6, C-peptide, and non-HMW adiponectin to
the multivariable model significantly increased the
AUC for the prediction of HCC from 0.766 to 0.876,
whereas addition of the liver damage marker, GLDH,
to the multivariable model raised the AUC from
0.769 to 0.813 (Fig. 2). When inflammatory and met-
abolic biomarkers were added to the model, the IDI
was 0.81 and the NRI was 0.63 (P< 0.0001),
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indicating strong reclassification improvement, whereas
when GLDH was added to the model, the IDI was
0.24 and the NRI was 0.46 (P5 0.07), indicating
moderate improvement. Addition of CRP, IL-6, C-
peptide, and non-HMW adiponectin to the multivari-
able model that additionally included AFP significantly
increased the AUC for the prediction of HCC from
0.777 to 0.855; GLDH increased the AUC from 0.803
to 0.836 (Fig. 3). When inflammatory and metabolic
biomarkers were added to the model, the IDI was 0.43,
and NRI(>0) was 0.44 (P5 0.0004), indicating moder-
ate reclassification improvement; when GLDH was
added to the model, the IDI was 0.10 and the
NRI(>0) was 0.21 (P5 0.29), indicating weak
improvement (Fig. 3).
Sensitivity Analyses. After exclusion of cases that
occurred during the first 2 years of follow-up, the asso-
ciations of the biomarkers with HCC were not sub-
stantially changed, except for CRP and non-HMW
adiponectin, which were no longer statistically signifi-
cant (IRR, 1.10; 95% CI 0.88-1.37; P5 0.12; and
1.63; 95% CI: 0.86-3.05; P5 0.12; Supporting Table
2). The association with CRP was also attenuated and
lost statistical significance after excluding cases with
Table 3. Relative Risks (95% Confidence Intervals) of HCC Across Tertiles of Prediagnostic Biomarker Concentrations in the
European Prospective Investigation into Cancer and Nutrition Cohort, 1992-2006
Biomarkers
Tertiles
P Value for
Linear Trend
Continuously Per Doubling of
Biomarker Concentrations
T1 T2 T3 RR (95% CI) P Value
Median CRP, mg/L 0.3 1.1 3.2
Number, cases/controls 33/89 32/68 60/86
Crude model* 1.00 (Reference) 1.32 (0.74-2.35) 1.98 (1.19-3.28) 0.02 1.25 (1.10-1.42) 0.0007
Multivariable model† 1.00 (Reference) 1.12 (0.54-2.36) 1.41 (0.67-2.96) 0.05 1.22 (1.02-1.46) 0.03
Median IL-6, pg/Ml 0.8 1.8 3.1
Number, cases/controls 20/73 8/37 64/68
Crude model* 1.00 (Reference) 1.04 (0.37-2.91) 4.65 (2.05-10.54) <0.0001 1.99 (1.48-2.66) <0.0001
Multivariable model† 1.00 (Reference) 0.73 (0.17-3.10) 3.85 (1.31-11.38) 0.004 1.90 (1.30-2.77) 0.001
Median C-peptide, ng/mL 1.2 2.1 3.9
Number, cases/controls 16/72 32/75 70/83
Crude model* 1.00 (Reference) 2.10 (1.03-4.22) 5.74 (2.64-12.45) <0.0001 2.49 (1.77-3.50) <0.0001
Multivariable model† 1.00 (Reference) 1.30 (0.52-3.24)) 3.13 (1.20-8.12) 0.009 2.25 (1.43-3.54) 0.0005
Median total adiponectin, mg/mL 2.9 4.9 8.3
Number, cases/controls 41/94 33/78 51/74
Crude model* 1.00 (Reference) 1.06 (0.61-1.82) 1.84 (1.02-3.30) 0.03 1.76 (1.23-2.51) 0.001
Multivariable model† 1.00 (Reference) 1.12 (0.55-2.26) 1.50 (0.69-3.28) 0.29 1.66 (1.04-2.63) 0.03
Median HMW adiponectin, mg/mL 1.3 2.5 4.9
Number, cases/controls 38/100 39/72 48/74
Crude model* 1.00 (Reference) 1.44 (0.86-2.42) 1.94 (1.08-3.48) 0.03 1.42 (1.09-1.85) 0.009
Multivariable model† 1.00 (Reference) 1.01 (0.51-1.98) 1.74 (0.78-3.88) 0.15 1.32 (0.93-1.88) 0.12
Median non-HMW adiponectin, mg/mL 1.6 2.4 3.5
Number, cases/controls 31/89 38/84 56/73
Crude model* 1.00 (Reference) 1.37 (0.75-2.48) 2.77 (1.49-5.16) 0.001 2.30 (1.45-3.64) 0.0004
Multivariable model† 1.00 (Reference) 1.63 (0.79-3.36) 2.62 (1.17-5.89) 0.02 2.09 (1.19-3.67) 0.01
Median leptin, ng/mL 3.0 7.9 19.8
Number, cases/controls 36/99 46/76 43/71
Crude model* 1.00 (Reference) 1.70 (1.00-2.89) 1.92 (1.02-3.63) 0.08 1.35 (1.11-1.64) 0.003
Multivariable model† 1.00 (Reference) 1.46 (0.72-2.95) 1.18 (0.43-3.26) 0.94 1.31 (0.92-1.86) 0.13
Median fetuin-A, lg/mL 164.6 203.3 245.8
Number, cases/controls 40/83 38/92 47/71
Crude model* 1.00 (Reference) 0.82 (0.46-1.43) 1.51 (0.83-2.73) 0.18 2.38 (1.05-5.42) 0.03
Multivariable model† 1.00 (Reference) 1.22 (0.59-2.52) 1.54 (0.75-3.14) 0.23 2.63 (0.93-7.49) 0.07
Median GLDH (mmol/sec/L) 27 52.5 118
Number, cases/controls 20/72 18/81 87/91
Crude model* 1.00 (Reference) 0.73 (0.34-1.55) 3.84 (2.07-7.13) <0.0001 1.88 (1.52-2.33) <0.0001
Multivariable model† 1.00 (Reference) 0.86 (0.34-2.17) 2.83 (1.32-6.08) 0.002 1.62 (1.25-2.11) 0.0003
*The crude model is based on conditional logistic regression, taking into account matching factors: study center; gender; age (612 months); date (62 months);
fasting status (<3, 3-6, or >6 hours); and time of the day (63 hours) at blood collection. Women were additionally matched according to menopausal status
(pre-, peri- [unknown], or postmenopausal) and exogenous hormone use (yes, no, or missing) at blood donation.
†The multivariable model takes into account matching factors with additional adjustment for education (no school degree or primary school, secondary school,
high school, or missing), smoking (never, former, current, or missing), alcohol at baseline, drinking status at baseline (nondrinker or drinker), diabetes (no, yes, or
missing), coffee (g/day), HBsAg/anti-HCV (negative, positive, or missing), BMI, and WHtR adjusted for BMI. P values for trends were calculated using median bio-
marker levels within tertiles among controls.
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underlying HBsAg/anti-HCV infection (IRR, 1.17;
95% CI: 0.95-1.45; P5 0.12; Supporting Table 2).
After excluding individuals with high alcohol con-
sumption, the main results remained essentially unal-
tered. Similarly, no substantial changes in risk estimates
were seen after exclusion of cases with prevalent diabe-
tes, with the exception of the estimated risk of fetuin-a
and HCC, which became statistically significant (IRR,
5.64; 95% CI: 1.60-19.89; Supporting Table 2).
Because of the small number of cases, these analyses
should be interpreted with caution. Finally, the associa-
tions were also not altered when we restricted the analy-
ses on HCC to histologically confirmed cases.
Discussion
In this prospective, nested, case-control study,
higher-circulating concentrations of IL-6, CRP, C-
peptide, non-HMW adiponectin, and GLDH were sig-
nificantly associated with higher risk of HCC, inde-
pendent of established liver cancer risk factors and
obesity parameters. Furthermore, our data suggest
these biomarkers to be able to improve the risk assess-
ment of HCC, beyond established liver cancer risk fac-
tors, therefore suggesting their potential application for
identification of individuals at high risk of cancer.
In animal models, it was shown that obesity may
promote HCC development through elevated produc-
tion of tumor necrosis factor and IL-6.35 In clinical
studies, higher levels of IL-6 and CRP have been
found among patients with HCC, when compared to
controls.36,37 Chronic inflammation is associated with
persistent liver injury and consecutive regeneration,
potentially leading to fibrosis and cirrhosis and, conse-
quently, to the development of HCC.38 Chronic
inflammation may also originate from hepatotropic
viruses, toxins, or impaired autoimmunity.39 Mecha-
nisms that link inflammation and liver cancer are not
completely understood, but transcription factors of the
nuclear factor kappa B family and signal transducer
and activator of transcription 3, cytokines such as IL-
6, and ligands of the epidermal growth factor receptor
family are pivotal players.39,40 In line with our find-
ings, a recent case-control study nested in a Japanese
cohort with 188 HCC cases and 605 controls reported
Fig. 2. Predictive ability of inflammatory and metabolic biomarkersa and GLDH beyond the multivariable adjusted modelb. aThe biomarkers included
in the model have been associated with HCC risk. These include CRP, Il-6, C-peptide, and non-HMW adiponectin. bMultivariable model taking into
account matching factors: study center; gender; age (612 months); date (62 months), fasting status (<3, 3-6, or>6 hours); and time of the day (63
hours) at blood collection. Women were additionally matched according to menopausal status (pre-, peri- [unknown], or postmenopausal) and exoge-
nous hormone use (yes, no, or missing) at blood donation. Further adjusted for education (no school degree or primary school, secondary school, high
school, or missing), smoking (never, former, current, or missing), alcohol at baseline, drinking status at baseline (nondrinker or drinker), diabetes (no,
yes, or missing), coffee (g/day), HBsAg/anti-HCV (negative, positive, or missing), BMI, and WHtR adjusted for BMI. Note: Analyses were based on overall
293 cases and 581 controls for adiponectin, 293 cases and 577 controls for CRP and GLDH, and 277 cases and 549 controls for C-peptide. For this
analysis, missing values for IL-6 (33 cases and 72 controls) were substituted with sex- and case-control–specific median values.
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relative risks (95% CI) of 1.94 (0.72-5.51) for CRP
and 5.12 (1.54-20.1) for Il-6 for the highest tertile of
biomarker distribution versus the lowest after multivari-
able adjustment.41 Interestingly, a recent study observed
a lower risk of HCC among aspirin users, providing
additional means for cancer prevention.42
Hyperinsulinemia is often present in patients with
chronic hepatitis C and is associated with more advanced
HCV-related hepatic fibrosis.43 Clinical studies suggested
that IR is significantly associated with HCC develop-
ment in patients with chronic HCV infection.44,45 Our
data suggest that C-peptide, as a marker of hyperinsulin-
emia, is strongly positively associated with risk of HCC
and IBD cancer, even after adjusting for HBV/HCV
infection and inflammation, giving support to the
hypothesis that hyperinsulinemia may increase risk of
HCC and IBD cancer. High insulin levels may directly
promote cell proliferation and survival through the phos-
phoinositide 3-kinase/protein kinase B and Ras/mitogen-
activated protein kinase pathways.46,47 Insulin may also
interact with leptin and adiponectin (see below).
Adiponectin is involved in the regulation of energy
homeostasis, vascular reactivity, inflammation, cell pro-
liferation, and tissue remodeling.48,49 It primarily acts
Table 4. Relative Risks (95% Confidence Intervals) of GBTC Across Tertiles of Prediagnostic Biomarker Concentrations in the
European Prospective Investigation Into Cancer and Nutrition Cohort, 1992-2006
Biomarkers
Tertiles
P Value for
Linear Trend
Continuously Per Doubling of
Biomarker Concentrations
T1 T2 T3 RR (95% CI) P Value
Median CRP, mg/L 0.3 1.1 3.2
Number, cases/controls 29/93 47/93 58/81
Crude model* 1.00 (Reference) 1.61 (0.95-2.74) 2.29 (1.35-3.89) 0.03 1.24 (1.08-1.42) 0.002
Multivariable model† 1.00 (Reference) 1.57 (0.89-2.76) 2.26 (1.26-4.07) 0.009 1.22 (1.05-1.42) 0.01
Median IL-6 (pg/Ml) 0.8 1.8 3.1
Number, cases/controls 37/96 30/51 32/54
Crude model* 1.00 (Reference) 1.71 (0.88-3.31) 1.72 (0.83-3.55) 0.15 1.28 (0.97-1.68) 0.08
Multivariable model† 1.00 (Reference) 1.69 (0.81-3.54) 1.19 (0.54-2.62) 0.68 1.15 (0.85-1.56) 0.35
Median C-peptide, ng/mL 1.2 2.1 3.9
Number, cases/controls 46/86 37/83 44/86
Crude model* 1.00 (Reference) 0.84 (0.46-1.50) 0.92 (0.50-1.70) 0.96 1.10 (0.82-1.48) 0.50
Multivariable model† 1.00 (Reference) 0.77 (0.41-1.44) 0.77 (0.39-1.52) 0.58 1.09 (0.79-1.51) 0.59
Median total adiponectin, mg/mL 2.9 4.9 8.3
Number, cases/controls 41/82 36/91 57/95
Crude model* 1.00 (Reference) 0.50 (0.45-1.41) 1.32 (0.72-2.42) 0.25 1.18 (0.84-1.65) 0.34
Multivariable model† 1.00 (Reference) 0.87 (0.48-1.58) 1.82 (0.93-3.53) 0.04 1.43 (0.98-2.10) 0.07
Median HMW adiponectin, mg/mL 1.3 2.5 4.9
Number, cases/controls 36/81 39/89 59/98
Crude model* 1.00 (Reference) 1.00 (0.57-1.77) 1.53 (0.84-2.82) 0.11 1.10 (0.85-1.43) 0.48
Multivariable model† 1.00 (Reference) 1.21 (0.65-2.23) 2.39 (1.20-4.76) 0.009 1.27 (0.94-1.72) 0.12
Median non-HMW adiponectin, mg/mL 1.6 2.4 3.5
Number, cases/controls 44/89 36/85 54/94
Crude model* 1.00 (Reference) 0.80 (0.45-1.45) 1.23 (0.67-2.24) 0.41 1.26 (0.83-1.89) 0.28
Multivariable model† 1.00 (Reference) 0.98 (0.52-1.87) 1.75 (0.89-3.42) 0.08 1.54 (0.98-2.42) 0.06
Median leptin, ng/mL 3.0 7.9 19.8
Number, cases/controls 35/73 52/88 47/107
Crude model* 1.00 (Reference) 1.25 (0.78-2.16) 0.84 (0.45-1.57) 0.37 0.99 (0.82-1.20) 0.91
Multivariable model† 1.00 (Reference) 1.00 (0.56-1.68) 0.52 (0.24-1.13) 0.05 0.89 (0.70-1.13) 0.35
Median fetuin-A (lg/mL) 164.6 203.3 245.8
Number, cases/controls 36/92 45/85 53/91
Crude model* 1.00 (Reference) 1.47 (0.83-2.56) 1.67 (0.93-3.03) 0.09 1.80 (0.79-4.14) 0.16
Multivariable model† 1.00 (Reference) 1.49 (0.83-2.69) 1.42 (0.74-2.70) 0.30 1.41 (0.55-3.60) 0.47
Median GLDH, mmol/sec/L 27 52.5 118
Number, cases/controls 38/97 44/85 52/84
Crude model* 1.00 (Reference) 1.41 (0.82-2.42) 1.81 (1.03-3.17) 0.05 1.22 (1.02-1.48) 0.03
Multivariable model† 1.00 (Reference) 1.32 (0.75-2.33) 1.55 (0.86-2.78) 0.17 1.15 (0.95-1.40) 0.15
*The crude model is based on conditional logistic regression, taking into account matching factors: study center; gender; age (612 months); date (62 months);
fasting status (<3, 3-6, or >6 hours); and time of the day (63 hours) at blood collection. Women were additionally matched according to menopausal status
(pre-, peri- [unknown], or postmenopausal) and exogenous hormone use (yes, no, or missing) at blood donation.
†The multivariable model takes into account matching factors with additional adjustment for education (no school degree or primary school, secondary school,
high school, or missing), smoking (never, former, current, or missing), alcohol at baseline, drinking status at baseline (nondrinker or drinker), diabetes (no, yes, or
missing), coffee (g/day), HBsAg/anti-HCV (negative, positive, or missing), BMI, and WHtR adjusted for BMI. P values for trends were calculated using median bio-
marker levels within tertiles among controls.
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as an insulin-sensitizing agent,50 but may also inhibit
cancer cell growth,51 induce apoptosis,52 and thus be
directly implicated in cancer.53 High adiponectin con-
centrations have been found to be associated with
lower risks of prostate, breast, endometrial, colo-
rectal,54 and pancreatic cancer.55 In contrast, in our
study, higher adiponectin levels were associated with
higher risk of HCC. Whereas this may be surprising,
given the beneficial aspects attributed to adiponectin,
this is in line with previous studies that found adipo-
nectin positively correlated with hepatic inflammation
in patients with chronic liver disease56 and with
HCV-related HCC.57 We also observed that non-
HMW adiponectin, but not HMW adiponectin, was
significantly associated with risk of HCC. Further-
more, the association between non-HMW adiponectin
and HCC risk was statistically largely accounted for
by IL-6. Because low-molecular forms of adiponectin
are more closely associated with inflammation com-
pared to high-molecular forms,58 we speculate
whether IL-6 may act as a mediator in these
associations.
Table 5. Relative Risks (95% CIs) of IBD Across Tertiles of Prediagnostic Biomarker Concentrations in the European Prospec-
tive Investigation into Cancer and Nutrition Cohort, 1992-2006
Biomarkers
Tertiles
P Value for
Linear Trend
Continuously Per Doubling of
Biomarker Concentrations
T1 T2 T3 RR (95% CI) P Value
Median CRP, mg/L 0.3 1.1 3.2
Number, cases/controls 6/20 7/22 21/25
Crude model* 1.00 (Reference) 0.81 (0.22-2.96) 3.29 (1.00-10.77) 0.02 1.31 (1.00-1.71) 0.05
Multivariable model† 1.00 (Reference) 0.86 (0.15-5.10) 3.92 (0.78-19.68) 0.05 1.43 (0.97-2.11) 0.07
Median IL-6, pg/Ml 0.8 1.8 3.1
Number, cases/controls 5/11 3/11 15/18
Crude model* 1.00 (Reference) 0.47 (0.07-3.29) 1.87 (0.43-8.12) 0.22 1.38 (0.75-2.52) 0.30
Multivariable model† 1.00 (Reference) NA NA NA 3.81 (0.42-34.50?) 0.23
Median C-peptide, ng/mL 1.2 2.1 3.9
Number, cases/controls 5/24 14/26 12/14
Crude model* 1.00 (Reference) 2.05 (0.66-6.41) 5.52 (1.24-24.54) 0.03 1.96 (0.94-4.11) 0.07
Multivariable model† 1.00 (Reference) 1.38 (0.36-5.30) 9.89 (1.21-80.45) 0.03 1.86 (0.78-4.42) 0.16
Median total adiponectin, mg/mL 2.9 4.9 8.3
Number, cases/controls 15/16 8/26 11/25
Crude model* 1.00 (Reference) 0.32 (0.10-1.01) 0.47 (0.16-1.37) 0.25 0.67 (0.35-1.25) 0.20
Multivariable model† 1.00 (Reference) 0.44 (0.11-1.76) 0.42 (0.11-1.29) 0.23 0.62 (0.27-1.41) 0.25
Median HMW adiponectin, mg/mL 1.3 2.5 4.9
Number, cases/controls 13/12 10/34 11/21
Crude model* 1.00 (Reference) 0.32 (0.12-0.89) 0.54 (0.18-1.62) 0.55 0.75 (0.46-1.21) 0.24
Multivariable model† 1.00 (Reference) 0.45 (0.12-1.58) 0.55 (0.14-2.12) 0.52 0.74 (0.41-1.35) 0.32
Median non-HMW adiponectin, mg/mL 1.6 2.4 3.5
Number, cases/controls 11/15 14/25 9/27
Crude model* 1.00 (Reference) 0.78 (0.27-2.27) 0.43 (0.13-1.41) 0.15 0.45 (0.14-1.48) 0.19
Multivariable model† 1.00 (Reference) 0.65 (0.17-2.47) 0.32 (0.07-1.42) 0.13 0.52 (0.18-1.50) 0.22
Median leptin, ng/mL 3.0 7.9 19.8
Number, cases/controls 8/21 11/30 15/16
Crude model* 1.00 (Reference) 1.25 (0.38-4.07) 3.81 (0.94-15.42) 0.03 1.61 (1.03-2.50) 0.03
Multivariable model† 1.00 (Reference) 1.19 (0.19-7.39) 3.73 (0.36-38.47) 0.14 1.52 (0.75-3.08) 0.25
Median fetuin-A, lg/mL 164.6 203.3 245.8
Number, cases/controls 8/19 7/16 19/32
Crude model* 1.00 (Reference) 1.05 (0.32-3.46) 1.50 (0.50-4.53) 0.43 2.29 (0.47-11.23) 0.31
Multivariable model† 1.00 (Reference) 0.43 (0.06-3.13) 1.75 (0.36-8.50) 0.23 2.74 (0.34-22.26) 0.34
Median GLDH, mmol/sec/L 27 52.5 118
Number, cases/controls 4/22 11/26 19/19
Crude model* 1.00 (Reference) 4.07 (0.79-20.78) 22.96 (3.08-171.40) 0.002 4.92 (2.01-12.0) 0.001
Multivariable model† 1.00 (Reference) 4.62 (0.62-34.50) 30.70 (2.19-429.60) 0.01 10.5 (2.20-50.90) 0.003
*The crude model is based on conditional logistic regression, taking into account matching factors: study center; gender; age (612 months); date (62 months);
fasting status (<3, 3-6, or >6 hours); and time of the day (63 hours) at blood collection. Women were additionally matched according to menopausal status
(pre-, peri- [unknown], or postmenopausal) and exogenous hormone use (yes, no, or missing) at blood donation.
†The multivariable model takes into account matching factors with additional adjustment for education (no school degree or primary school, secondary school,
high school, or missing), smoking (never, former, current, or missing), alcohol at baseline, drinking status at baseline (nondrinker or drinker), diabetes (no, yes, or
missing), coffee (g/day), HBsAg/anti-HCV (negative, positive, or missing), BMI, and WHtR adjusted for BMI. P values for trends were calculated using median bio-
marker levels within tertiles among controls.
Abbreviation: NA, not available.
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Leptin has angiogenic properties, promotes cell pro-
liferation and migration, and interacts with growth fac-
tors, all of which could promote tumor growth.59
Evidence on the role of leptin in non-alcoholic fatty
liver disease and cancer risk is controversial, with some
studies showing positive associations and others show-
ing null results.60,61 Our study does not support the
hypothesis that leptin levels are associated with liver
cancer risk. On the basis of the mechanistic evidence
obtained with cultured cells and tumor specimens, we
speculate that local, rather than systemic, leptin con-
centrations may be important for tumor progression.
In addition, leptin concentrations in plasma may be
affected by the soluble leptin receptor (sOB-R), a
marker related to diabetes and cancer risk62; however,
future studies are warranted to examine whether sOB-
R may be specifically related to liver cancer.
Fetuin-a is suggested to provide a link between fatty
liver and IR,63,64 thereby being potentially relevant for
liver cancer. In our data, a significant association of
fetuin-A with HCC risk was observed only after exclu-
sion of participants with prevalent diabetes at baseline.
Although these results may be the outcome of a chance
finding, we also speculate on whether mechanisms
other than insulin sensitivity may be more relevant
here.
High serum GLDH levels occur in liver diseases
with hepatocyte necrosis as the predominant event,
such as toxic liver damage or hypoxic liver disease, and
they have been useful in clinical practice in distin-
guishing between acute viral hepatitis and acute toxic
liver necrosis or acute hypoxic liver disease.65 In our
analysis, higher prediagnostic concentrations of GLDH
were associated with higher risks of HCC and IBD.
These data suggest that GLDH may be used as a
marker of hepatic injury in liver cancer pathogenesis
among ostensibly healthy subjects. Interestingly, in our
analysis, the associations for IL-6, C-peptide, and
non-HMW adiponectin with HCC risk remained stat-
istically significant after adjustment for GLDH, sug-
gesting that prevalent undiagnosed liver injury may
not account for these associations.
Strengths of our study include the prospective design
and the ability to control for established and putative
Fig. 3. Predictive ability of inflammatory and metabolic biomarkers and GLDH beyond the multivariable adjusted model and AFP levels. aThe
biomarkers included in the model have been associated with HCC risk. These include CRP, Il-6, C-peptide, and non-HMW adiponectin. bMultivari-
able model taking into account matching factors: study center; gender; age (612 months); date (62 months); fasting status (<3, 3-6, or >6
hours); and time of the day (63 hours) at blood collection. Women were additionally matched according to menopausal status (pre-, peri-
[unknown], or postmenopausal) and exogenous hormone use (yes, no, or missing) at blood donation. Further adjusted for education (no school
degree or primary school, secondary school, high school, or missing), smoking (never, former, current, or missing), alcohol at baseline, drinking
status at baseline (nondrinker or drinker), diabetes (no, yes, or missing), coffee (g/day), HBsAg/anti-HCV (negative, positive, or missing), BMI,
and WHtR adjusted for BMI. Note: Analyses were based on overall 293 cases and 581 controls for adiponectin, 293 cases and 577 controls for
CRP and GLDH, and 277 cases and 549 controls for C-peptide. For this analysis, missing values for IL-6 (33 cases and 72 controls) were sub-
stituted with sex- and case-control–specific median values.
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liver cancer risk factors and for a variety of circulating
metabolic biomarkers. Anthropometric data were
mostly measured, rather than self-reported, which
reduces the possibility of residual confounding by obe-
sity. Limitations of our study include a relatively small
number of incident cases, particularly for the analyses
of the inflammatory biomarkers, which limited the pos-
sibility to perform detailed stratified and sensitivity
analyses. The duration of follow-up was relatively short,
and concentrations of biomarkers may have been influ-
enced by preexisting undiagnosed disease. However, our
risk estimates did not appreciably change after exclusion
of patients who were diagnosed within the first 2 years
of follow-up. Because most of our study participants
were HBV/HCV negative, our findings are largely valid
for HCC of nonviral etiology. Because histologically
confirmed and probable HCC cases were included in
the analyses, a potential misclassification of liver cancer
cases may have occurred. However, when we performed
analyses only with histologically confirmed HCC cases,
the results did not change. Additionally, because the
distal part of the extrahepatic bile duct runs through
the head of the pancreas, some of the cancers classified as
GBTC may, in fact, be cancers of the pancreas and vice
versa. Our results are based on single assessments of expo-
sure variables within participants, and biomarkers may
be susceptible to short-term variation, which would bias
the results toward the null; however, most biomarkers
have shown relatively high reliability over time.66 Because
of the low prevalence of established risk factors (i.e.
HBV/HCV infection, diabetes, and alcohol consump-
tion) in this study population, we were not able to evalu-
ate whether biomarkers are specifically related to risk
among persons with known risk factors, which may be a
question of relevance to the clinical practice. We adjusted
our analysis for a number of potential risk factors of liver
cancer. Nevertheless, we cannot rule out the possibility of
residual confounding. Furthermore, given its observatio-
nal nature, our study does necessarily prove causation.
In conclusion, higher-circulating concentrations of
IL-6, CRP, C-peptide, non-HMW adiponectin, and
GLDH were significantly associated with higher risk of
HCC, independent of established liver cancer risk fac-
tors and obesity parameters. Further studies are war-
ranted to investigate the role of these inflammatory
and metabolic biomarkers as mediators of the relation
between obesity and liver cancer, as well as to explore
their potential applications for cancer prevention.
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